We examined the impact of HDL-associated PON1 in preventing MPO-mediated HDL MDA modification and dysfunction, and the potential role of reduced PON1 activity in promoting increased MDA modification and impaired function of HDL in FH patients. Here, PON1 is linked to familial hyperaldosteronism.